Therefore, it will be necessary to perform further studies including well controlled placebo matched clinical trials to document any beneficial effects of antioxidant/NOX4 inhibitory therapeutic interventions on the development or progression of the fibrotic process in SSc. This evidence concerns the gene NOX4 and systemic sclerosis.